论文部分内容阅读
来自于美国的研究人员报道说,通过检测HIV感染者的蛋白酶抑制剂(PI)突变的数量和类型可预测其对抗逆转录病毒药物的病毒学应答。美国食品药品管理局(FDA)的Lisa K．Naeger博士认为,弄清HIV感染者中的抗逆转录病毒抗性是确定接受过抗逆转录病毒治疗的患者下一个最佳治疗方案的关键所在。
Researchers from the United States reported that the virological response to antiretroviral drugs could be predicted by measuring the number and type of protease inhibitor (PI) mutations in HIV-infected individuals. Lisa K. from the U.S. Food and Drug Administration (FDA). Naeger believes that understanding antiretroviral resistance among HIV-infected patients is key to identifying the next best treatment option for patients who have received antiretroviral therapy.